

Form 603

Corporations Act 2001
Section 671B

Notice of initial substantial holder

To Company Name/Scheme	PYC Therapeutics Ltd
ACN/ARSN	098 391 961

1. Details of substantial holder (1)

Name	Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust
ACN/ARSN (if applicable)	001 987 739

The holder became a substantial holder on 12 / 06 / 2026

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary	49,500,193	49,500,193	5.03%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust	Power to control voting and/or disposal of securities	49,500,193 ordinary shares

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust	State Street Australia Limited as custodian for Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust	State Street Australia Limited as custodian for Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust	49,500,193 ordinary shares

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
Retail Employees Superannuation Pty Limited as trustee for the Retail Employees Superannuation Trust	See schedule	See schedule		See schedule

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association

7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Retail Employees Superannuation Pty Limited	Level 21,50 Bridge Street, Sydney, NSW, 2000
State Street Australia Limited	420 George Street, Sydney, NSW, 2000

Signature


print name

Jolanta Willetts

capacity

Company Secretary

sign here

Signed by:

55561182EBFC44E...

date

16 / 06 / 2026

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:

(a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

(b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
 - (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
-

Trade Date	Security Long Name	CUSIP NUMBER	Transaction Category Name	Shares/Par Value	Base Net Amount
DocuSign Envelope ID: 1D91E7B1-5012-86CC-8211-1E177FF45EC3					
24/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	3,168.000	3,380.23
24/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	38,355.000	40,924.46
29/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	22,145.000	25,654.14
29/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	268,129.000	310,617.33
30/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	39,092.000	47,432.86
30/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	3,229.000	3,917.96
31/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	732.000	880.04
31/01/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	8,864.000	10,656.69
03/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	42,121.000	49,905.44
03/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	3,479.000	4,121.96
04/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	240,562.000	288,611.69
04/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	19,868.000	23,836.43
05/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	11,704.000	14,018.30
05/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	141,706.000	169,726.32
06/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	45,672.000	54,835.68
06/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	3,772.000	4,528.81
10/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	185,299.000	240,151.03
10/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	15,304.000	19,834.28
11/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	8,817.000	11,476.47
11/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	106,755.000	138,955.46
27/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	15,518,329.000	19,397,911.25
27/02/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,281,671.000	1,602,088.75
04/03/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,547,430.000	1,934,606.65
07/03/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	3,061.000	3,768.72
10/03/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	9,019.000	11,301.77
01/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,481.000	1,758.27
01/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	18,519.000	21,986.06
02/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	97,011.000	114,609.29
02/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	7,761.000	9,168.89
03/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	4,377.000	5,018.41
03/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	54,709.000	62,726.06
04/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,329,761.000	1,465,472.42
04/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	106,381.000	117,237.92
07/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	19,758.000	20,418.50
07/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	296,377.000	306,284.56
08/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	15,314.000	15,964.02
08/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	229,701.000	239,450.83
09/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	283,682.000	282,393.53
09/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	18,912.000	18,826.09

Trade Date	Security Long Name	CUSIP NUMBER	Transaction Category Name	Shares/Par Value	Base Net Amount
Docusign Envelope ID: 1D91E7B1-5012-86CC-8211-1E177FF45EC3					
11/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	2,369.000	2,307.45
11/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	35,537.000	34,613.67
14/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	72,846.000	69,333.12
14/04/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,077,154.000	1,025,209.86
28/07/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	100,000.000	129,742.17
28/07/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,600,000.000	2,075,874.64
04/08/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	949,866.000	1,156,150.17
04/08/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	54,992.000	66,934.72
02/09/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	180,000.000	223,166.55
02/09/2025	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	2,400,000.000	2,975,553.90
12/02/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	12,752,021.000	19,128,031.50
12/02/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	939,878.000	1,409,817.00
08/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	2,259,336.000	2,568,864.31
08/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	160,664.000	182,674.91
09/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	1,142,943.000	1,285,226.47
09/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	81,276.000	91,393.95
10/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	163,200.000	187,097.41
10/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	11,605.000	13,304.33
13/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	252,075.000	287,927.09
13/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	17,925.000	20,474.43
14/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	14,934.000	17,226.88
14/04/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	210,014.000	242,258.31
05/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	36,532.000	45,671.83
05/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	522,999.000	653,846.66
09/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	37,216.000	45,297.03
09/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	532,784.000	648,471.86
09/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	30,685.000	37,060.23
09/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	439,285.000	530,552.56
10/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	439,313.000	519,301.70
10/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	30,687.000	36,274.39
10/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	15,672.000	18,258.51
10/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	224,358.000	261,386.14
11/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	20,240.000	23,541.94
11/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	289,760.000	337,031.26
12/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	327,148.000	396,525.06
12/06/2026	PYC THERAPEUTICS LTD COMMON STOCK	B06NPT903	BUY	22,852.000	27,698.13